TP53 and non-small cell lung carcinoma: An ongoing phase 1 clinical trial (NCT03567642) is testing the efficacy of combining the EGFR inhibitor, Osimertinib, with platinum/etoposide chemotherapy in patients with EGFR-mutant NSCLC that also possess RB1 and p53 mutations.